Síguenos en Twitter     Síguenos en Facebook     Síguenos en Google+     Síguenos en YouTube     Siguenos en Linkedin     Correo Grupsagessa     Gmail     Yahoo Mail     Dropbox     Instagram     Pinterest     Slack     Google Drive     Reddit     StumbleUpon     Print

SOBRE EL AUTOR **

Mi foto
FACP. Colegio de médicos de Tarragona Nº 4305520 / fgcapriles@gmail.com

WORLD EMERGENCY MEDICINE SOCIETIES

Rapid IJ (aka Easy Internal Jugular Cannulation)

Buscar en contenido

Contenido:

miércoles, 26 de agosto de 2015

Idarucizumab

Resultado de imagen de PulmCCM
PulmCCM - 25 August 2015
"New oral anticoagulants like dabigatran, apixaban and rivaroxaban have advantages over warfarin: not requiring regular monitoring for efficacy; faster onset of action; shorter half-lives. Unlike warfarin, they've had the significant disadvantage of having no proven antidote for the bleeding that inevitably occurs when any anticoagulant is given to thousands of people. [lawsuits]
Boehringer Ingelheim, makers of the direct thrombin inhibitor dabigatran, announced a solution in a new trial in the New England Journal of Medicine: idarucizumab, a monoclonal antibody that binds dabigatran with 350x the affinity of thrombin."
http://pulmccm.org/main/2015/cardiovascular-disease-review/idarucizumab-works-as-antidote-for-dabigatran-induced-bleeding/